Form 4: Galectin Therapeutics Director Plans Future Stock Purchase Under 10b5-1 Plan

Galectin Therapeutics Inc. Director Kevin D. Freeman has filed a Form 4 indicating a planned future purchase of 5,000 shares of common stock at $2.899 per share on July 17, 2025, under a Rule 10b5-1 trading plan.

Summary

• Kevin D. Freeman, a Director and 10% Owner of Galectin Therapeutics Inc. (GALT), filed a Form 4.
• The filing indicates a planned acquisition of 5,000 shares of GALT common stock.
• The transaction is scheduled for July 17, 2025, at a price of $2.899 per share.
• This purchase is being made pursuant to a Rule 10b5-1 trading plan, which allows insiders to pre-arrange trades.
• Following this planned transaction, Kevin D. Freeman's direct beneficial ownership will be 49,769 shares.
• Indirect beneficial ownership will include 80,000 shares held by Freeman Global Holdings LLC and 18,063 shares in an IRA, totaling 147,832 shares across all forms of ownership.

Sentiment

Score: 8

Explanation: The planned purchase by a Director and 10% Owner, especially under a 10b5-1 plan, indicates strong insider confidence in the company's future prospects and current valuation, which is generally a positive signal for investors.

Positives

• A Director and 10% Owner planning to increase their stake in the company signals confidence in future prospects.
• The purchase is being made at a specific price of $2.899 per share, indicating a valuation at which the insider is willing to invest.
• The transaction is part of a Rule 10b5-1 plan, which allows insiders to pre-arrange trades to avoid accusations of trading on material non-public information.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders may view this planned insider purchase as a positive signal, potentially increasing investor confidence and demand for the stock.
• Employees and other stakeholders might interpret the insider's investment as a sign of stability and belief in the company's long-term strategy.

Key Dates

Recommendation

Keywords

Galectin Therapeutics, GALT, SEC Form 4, Insider Trading, Stock Purchase, Director, 10b5-1 Plan, Equity Acquisition, Biotechnology, Pharmaceuticals